AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00265850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX or
Description: Patients receive oxaliplatin 85 mg/m\^2 IV infused over two hours followed by leucovorin 400 mg/m\^2 IV over 2 hours followed by 5-FU 400 mg/m\^2 IV bolus, then 2400 mg/m\^2 continuous IV infusion over 46-48 hours
Study NCT00265850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX or
Description: Patients receive oxaliplatin 85 mg/m\^2 IV infused over two hours followed by leucovorin 400 mg/m\^2 IV over 2 hours followed by 5-FU 400 mg/m\^2 IV bolus, then 2400 mg/m\^2 continuous IV infusion over 46-48 hours
Study NCT00265850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: Patients receive irinotecan 180 mg/m\^2 IV infused over 90 minutes followed by leucovorin 400 mg/m\^2 IV over 2 hours followed by 5-FU 400 mg/m\^2 IV bolus following leucovorin then 2400 mg/m\^2 continuous IV infusion over 46-48 hours.
Study NCT00265850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Patients receive irinotecan 180 mg/m\^2 IV infused over 90 minutes followed by leucovorin 400 mg/m\^2 IV over 2 hours followed by 5-FU 400 mg/m\^2 IV bolus following leucovorin then 2400 mg/m\^2 continuous IV infusion over 46-48 hours.
Study NCT02627521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor administration prior to randomization
Study NCT00549081 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHEA
Description: oral DHEA tablets 75 mg daily
Study NCT04282824 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT
Study NCT04282824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68-labeled PSMA-11
Description: Given IV
Study NCT01422590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitiglinide
Description: Single oral administration of mitiglinide 10 mg
Study NCT01422590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin, Mitiglinide
Description: Concomitant administration of sitagliptin 100 mg and mitiglinide 10 mg
Study NCT03583320 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac CT angiogram
Description: To the best of the author's knowledge this study will provide the first prospective and randomised data pertaining to hospital length of stay as a primary outcome in the use of CTCA on this acute chest pain cohort (with an intermediate observational zone category) on initial high sensitivity-cardiac troponin (hs-cTn) results presenting to the emergency department in a tertiary care hospital.
Study NCT04229784 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrewuency surgery
Description: The research procedure consists of radiofrequency destruction of hemorrhoidal vascular tissue. It consists in delivering a 4 MHz radiofrequency wave current delivered at low temperature by microfibre electrodes using a large disposable needle within the hemorrhoidal vascular tissue
Study NCT01665924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634 100mg capsule once a day for 10 days
Study NCT01202812 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)
Description: Eicosapentaenoic Acid (EPA)/Docosahexaenoic Acid (DHA) 30mg/kg (LOVAZA capsules) given by mouth daily for 6 months.
Study NCT01202812 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsules
Description: Placebo capsules given by mouth daily for 6 months.
Study NCT05517915 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training.
Description: Interval inspiratory muscle training was performed using the inspiratory muscle trainer.
Study NCT05517915 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham inspiratory muscle training.
Description: Interval inspiratory muscle training was performed using the unloaded inspiratory muscle trainer.
Study NCT04425512 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Complete Blood Count
Description: Complete Blood Count samples
Study NCT04425512 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Complete Blood Count
Description: Complete Blood Count samples
Study NCT04425512 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Complete Blood Count
Description: Complete Blood Count samples
Study NCT02407041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR-MD-02
Description: IV infusion
Study NCT02601443 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical Pessary
Study NCT02567617 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Polyphenols
Description: Capsules with five substances (polyphenols) at a concentration of 3000mg per day
Study NCT02567617 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo controlled
Description: Starch capsules
Study NCT03402152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRX-101
Description: NRX-101, a fixed dose combination of D-cycloserine+lurasidone will be given twice a day by mouth
Study NCT03402152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone HCl
Description: Lurasidone HCl will be given twice a day by mouth
Study NCT03402152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral capsule
Study NCT00823524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: donor natural killer cell infusion
Description: give patients donor-derived NK cells 2 to 3 weeks after HLA-haploidentical hematopoietic cell transplantation
Study NCT01196650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IN 10 003 formulation A
Study NCT01196650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IN 10 003 formulation B
Study NCT01196650 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Study NCT00789191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: The detemir insulin dose is injected subcutaneously (under the skin) once daily in the evening and will be titrated (individually adjusted) weekly throughout the trial.
Study NCT00789191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: The sitagliptin dose is 100 mg/ day and should be kept stable throughout the trial. Frequency of sitagliptin is once daily.
Study NCT00789191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin
Description: The sitagliptin dose is 100 mg/ day and should be kept stable throughout the trial. Frequency of sitagliptin is once daily.
Study NCT00789191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Metformin treatment with at least 1000 mg/ day. Dose and dosing frequency should remain unchanged throughout the trial.
Study NCT00789191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Metformin treatment with at least 1000 mg/ day. Dose and dosing frequency should remain unchanged throughout the trial.
Study NCT00789191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulphonylurea
Description: Sulphonylurea (SU) dose and dosing frequency should initially remain unchanged. In case of hypoglycaemia SU dose may be reduced at the discretion of the investigator.
Study NCT03006471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 10 mg, one per day before breakfast during 12 weeks.
Study NCT03006471 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Cap
Description: one per day before breakfast during 12 weeks.
Study NCT02284685 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting Eating Disorder Treatment among College Students
Description: Online intervention designed to identify and increase help-seeking among undergraduates with previously undiagnosed/untreated eating disorders
Study NCT01009983 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: panitumumab
Description: Given IV
Study NCT01009983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT01009983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT01009983 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative study
Study NCT01009983 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative study
Study NCT00223691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: 10-50 mg, PO. Single dose. Alone or in combination with Yohimbine or Mestinon.
Study NCT00223691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose
Description: 25-100 mg, PO. Single dose.
Study NCT00223691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridostigmine Bromide
Description: 30 mg-180 mg PO. Single dose. Alone or in combination with Yohimbine or atomoxetine.
Study NCT00223691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yohimbine
Description: 2.7, 5.4 or 10.8 mg PO. Single dose. Alone or in combination with Atomoxetine or Pyridostigmine.
Study NCT00223691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine HCl
Description: 2.5, 5.0, 7.5, 10 mg PO. Single dose
Study NCT00223691 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: PO.Single dose.
Study NCT00223691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: 50-400 mg PO. Single dose
Study NCT04282824 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Monosodium Glutamate
Description: Given PO
Study NCT00223691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: 5-50 µg, S.C. Single dose.
Study NCT00223691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water intake
Description: Tap water 2 onz., 8 oz., 16 oz. PO, alone or in combination with any of the above medications. Single dose.
Study NCT00223691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine Hydrochloride
Description: 12.5 mg-100 mg PO. Single dose. Alone or in combination with Ranitidine
Study NCT00223691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine HCL
Description: 150-300 mg PO. Single dose. Alone or in combination with Diphenhydramine.
Study NCT00223691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranylcypromine
Description: 5 - 40 mg PO. Single dose
Study NCT00223691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergotamine/ Caffeine
Description: Ergotamine: 1.0 mg PO. Single dose. Caffeine 100 mg PO.Single dose
Study NCT00223691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 50-200 mg PO. Single dose
Study NCT00223691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine
Description: 15, 30 or 60 mg, PO. Single dose.
Study NCT00223691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: 5 or 10 mg PO. Single dose.
Study NCT00223691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: 25, 50 or 75 mg, PO. Singe dose.
Study NCT00223691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 300, 600 or 900 mg, PO. Single dose.
Study NCT00223691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymetazoline 0.05% nasal solution
Description: 1-2 sprays/ nostril. Single dose.
Study NCT04282824 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT00006349 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin E
Study NCT00006349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donepezil hydrochloride
Study NCT00006349 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT04019509 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: blood test
Description: blood test for thyroid antibodies and thyroid function (TSH, FT4)
Study NCT04019509 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: follow up treatment outcome
Description: questionnaire for treatment outcome: pregnancy, no pregnancy, miscarriage, delivery
Study NCT02432950 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Participate in the PNP
Study NCT02432950 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Participate in the PNP
Study NCT02432950 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01099059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine
Description: Amantadine 100-150 mg depending on weight (100 mg/day for \<30 Kg and 150 mg/day for >30 Kg)
Study NCT01099059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ritalin
Description: ritalin at a dose of 20-30 mg/day depending on weight (20 mg/day for \<30 Kg and 30 mg/day for >30 Kg)
Study NCT03026972 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo drug contains 20mg mannitol and 10 millimole(mM) phosphate buffer(PB).population I～population IV are coxal muscle injection of placebo.
Study NCT03026972 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose adjuvant
Description: Population I and polulation IV are coxal muscle injection of low dose adjuvant.
Study NCT03026972 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose adjuvant
Description: Population II ,Population III and Population IV are coxal muscle injection of high dose adjuvant.
Study NCT03026972 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose vaccine
Description: Population I and population IV are coxal muscle injection of low dose vaccine.
Study NCT03026972 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose vaccine
Description: Population II,population III and population IV are coxal muscle injection of high dose vaccine .
Study NCT01661179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib 300mg
Description: 300 mg oral dose once daily (100 mg x 3 tablets)
Study NCT00321737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR
Description: Dexlansoprazole MR 30 mg, capsules, orally, once daily for up to six months.
Study NCT00321737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR
Description: Dexlansoprazole MR 60 mg, orally, once daily for up to six months.
Study NCT00321737 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.
Study NCT00145639 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ifosfamide, Carboplatin, Doxorubicin
Description: See Detailed Description for treatment plan.
Study NCT00145639 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Limb Sparing
Description: See Detailed Description for treatment plan.
Study NCT03542084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unsolicited endocrine e-consult
Description: The PCP for intervention arm patients will receive an unsolicited e-consult from an endocrinologist with recommendations on how to improve glycemic control in the intervention patient
Study NCT04715360 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: autologous activated platelet-rich plasma
Description: Patient received standard medication for COVID-19 management and autologous activated platelet-rich plasma on day 1, 3 and 5 while patient in ICU. On day 0, 4 and 6, hematology analysis, multicytokines measurement and thorax X-ray were done to each patient
Study NCT04715360 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Avigan
Description: Patient received avigan 2x1,600 mg for a day, followed by 2x600 mg for five consecutive days.
Study NCT04715360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avigan
Description: Patient received avigan 2x1,600 mg for a day, followed by 2x600 mg for five consecutive days.
Study NCT06309446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zoralan Wound
Description: Topical application of approximately 0.2 g per test field (approx. 1.2 cm in diameter each) once daily during a 12-day treatment period (11 treatments).
Study NCT00713687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Oxaliplatin, Photodynamic therapy (Photosan®)
Description: 1. Photodynamic therapy (PDT) after successful drainage:~   Photosan® 2 mg/kg i.v. 48 hrs before laser activation~2. 9 cycles of GemOx chemotherapy (start 4 weeks after PDT):~   * Gemcitabine 1000 mg/m² 100 min infusion on day 1 of chemotherapy~  * Oxaliplatin 100 mg/m² 2h infusion on day 2 of chemotherapy~  * iteration every 14 days~  * afterwards 4 weeks intermission~3. Iteration of 1. and 2. in case of good compatibility
Study NCT03694587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 200 mg TEPI Medicated Plaster
Description: Ibuprofen 200mg TEPI medicated plaster applied to the upper back daily for 24 hours for 5 days
Study NCT00223691 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bovril
Description: 6-10 g, PO. Single dose.
Study NCT00223691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: 125-1000 mg PO. Single dose. Alone or in combination with yohimbine or midodrine
Study NCT00223691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine tartrate
Description: 1.5-6 mg PO. Single dose.
Study NCT00223691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa/levodopa
Description: 10mg/100mg or 25mg/100mg. 1-2 tab PO. Single dose. Alone or in combination with carbidopa (Lodosyn) 25-175 mg
Study NCT00223691 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inflatable abdominal binder
Description: External abdominal compression (20-40 mm Hg) with an inflatable abdominal binder applied after a pressor agent (e.g. midodrine, yohimbine).
Study NCT01681966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRF110- oily solution (Ropivacaine)
Description: Post operative application of PRF110-oily solution (Ropivacaine)
Study NCT03096275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMF
Description: Patients were treated with Glucocorticoids combined with methotrexate and mycophenolate mofetil
Study NCT00223691 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: inflatable abdominal binder (sham)
Description: External abdominal compression (5 mm Hg) with an inflatable abdominal binder applied after a pressor agent (e.g. midodrine, yohimbine).
Study NCT03110198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalazine
Description: Mesalazine enema rectal administration at bedtime 4g/100 ml, once daily
Study NCT03110198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrocortisone sodium succinate
Description: hydrocortisone sodium succinate rectal administration at bedtime 100mg/100 ml, once daily
Study NCT01310010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Treatment with 100 mg QD of dasatinib (Sprycel®) administered orally as continuous daily dosing (CDD).
Study NCT01071954 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Administered by subcutaneous injection once a week.
Study NCT03097289 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trima Accel system
Description: A platelet apheresis procedure involves connecting the blood in the donor's vein through tubing to a machine that separates the blood components. After the separation, the desired component of the blood is removed (platelets and plasma), while the remainder of the blood components are reinfused back into the patient. To prevent clotting, an anticoagulant (ACDA) is used throughout the procedure. Following each blood collection, Platelet Additive Solution (PAS), InterSol, will be added to the platelet product to prepare the final product for 5 day storage. The entire procedure is painless and should take 90 to 120 minutes.
Study NCT00501644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC of 5 by 1 hour IV infusion every 28 days.
Study NCT00501644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF (Sargramostim)
Description: Starting dose of 400 mg injected under the skin once a day for 7 days prior to and following each course of chemotherapy.
Study NCT00501644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Gamma
Description: 0.1 mg injected under the skin for 2 days before and after chemotherapy (Day 5 and Day 7 of each 7-day GM-CSF cycle).
Study NCT02835469 — intervention group
Intervention type: DRUG
Intervention: Menotrophin